Trinity Biotech's TRIstat HbA1c test:
This article was originally published in Clinica
Executive Summary
Irish diagnostics firm Trinity Biotech has gained US 510k approval of its TRIstat point-of-care HbA1c blood test. The TRIstat platform detects a patient's level of HbA1c, also known as glycated haemoglobin, a measure of their blood sugar control over the previous two to three months. The American Diabetes Association recommends that diabetic patients be tested for HbA1c at least four times a year. The test uses an affinity two-phase optical system, and can give results within minutes, the Dublin-based company claimed. Launch of the TRIstat product is slated for the first quarter of 2008. Trinity has not yet filed for CE-marking in Europe.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.